Cynthia Chmielewski | CureTalks
Cynthia attended Rutgers University graduating with degrees in Psychology and Education. Upon graduation she secured her first teaching position and immediately fell in love with her chosen profession. Cynthia continued teaching for 28 years. Now retired, Cynthia, a myeloma survivor, is using her passion for education to teach a new group of "students" - myeloma patients and their caregivers. She is on the advisory boards of the Patient Empowerment Network, the Myeloma Crowd and the Philadelphia Multiple Myeloma Networking Group. Using social media to educate is her passion. Cynthia educates and advocates by tweeting at @MyelomaTeacher and sharing myeloma resources, educational opportunities and clinical trial information on her MyelomaTeacher Facebook page. Ms. Chmielewski is the co-founder of the #MMSM TweetChat and is also a regular panelist on CureTalks Podcast. Cynthia was an invited panelist and presented posters on using social media in hematology at the annual meetings of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR) and the European Bone Marrow Transplant (EBMT). More recently Cynthia joined the Patient Engagement team at Patient Power. Additionally, she consults on educational projects sponsored by the Myeloma Crowd. She enjoys serving as a voting member on the IRB at the University of Pennsylvania, a peer reviewer for the NCI’s DEA grants program and a patient advocate on the Myeloma Steering Committee of the National Cancer Institute (NCI) and ACCRU. Cynthia has also participated in the Department of Defense’s CMCRP grant reviews.
Related Talks
Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment
Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So, testing and quantifying…
The MMRF Precision Medicine Model – How Close to Multiple Myeloma Cure Are We?
The MMRF has built a unique model that provides the only end-to-end solution in cancer research. This model is based on three interrelated…
Immunotherapy Advances in Multiple Myeloma
Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody…
High Risk Myeloma Treatment Options
Myeloma is classified as high-risk based on presence of cytogenetic abnormalities and poor treatment outcomes. Despite many new drugs and drug combinations being…
Demystifying Palliative Care (Supportive Care)
Palliative care is often confused with hospice. Very few people are aware that palliative care deals with the quality of life of patients…